Talphera Inc. Total Liabilities
Talphera Inc. total liabilities. Based on the latest financial reports, Talphera Inc. (TLPH) has total liabilities worth $12.40 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TLPH asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Talphera Inc. (2008–2025)
Total liabilities of Talphera Inc. from 2008 to 2025. This chart illustrates how Talphera Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Talphera Inc. Competitors by Total Liabilities
The table below lists competitors of Talphera Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sambu Const
KO:001470
|
Korea | ₩315.90 Billion |
|
Here Group Limited
NASDAQ:HERE
|
USA | $323.57 Million |
|
Tu Liem Urban Development JSC
VN:NTL
|
Vietnam | ₫411.89 Billion |
|
Vbt Yazilim AS
IS:VBTYZ
|
Turkey | TL1.15 Billion |
|
WooriNet Inc
KQ:115440
|
Korea | ₩27.35 Billion |
|
Arlitech Electronic
TWO:6432
|
Taiwan | NT$461.80 Million |
|
Sensus Healthcare Inc
NASDAQ:SRTS
|
USA | $4.94 Million |
|
ROK Resources Inc
V:ROK
|
Canada | CA$35.39 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Talphera Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Talphera Inc. asset portfolio.
Liquidity & Leverage Metrics
Talphera Inc. Total Liabilities Ratios Explained
Talphera Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Talphera Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Talphera Inc. (2008–2025)
The table below shows the annual total liabilities of Talphera Inc. from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $12.68 Million | +23.93% |
| 2024-12-31 | $10.24 Million | +62.72% |
| 2023-12-31 | $6.29 Million | -75.50% |
| 2022-12-31 | $25.67 Million | -77.44% |
| 2021-12-31 | $113.79 Million | -6.77% |
| 2020-12-31 | $122.05 Million | -8.08% |
| 2019-12-31 | $132.77 Million | +14.18% |
| 2018-12-31 | $116.28 Million | +3.76% |
| 2017-12-31 | $112.06 Million | +6.39% |
| 2016-12-31 | $105.33 Million | +11.26% |
| 2015-12-31 | $94.67 Million | +138.11% |
| 2014-12-31 | $39.76 Million | +7.83% |
| 2013-12-31 | $36.87 Million | +20.21% |
| 2012-12-31 | $30.67 Million | +31.27% |
| 2011-12-31 | $23.37 Million | -67.87% |
| 2010-12-31 | $72.72 Million | +7.76% |
| 2009-12-31 | $67.48 Million | +20.48% |
| 2008-12-31 | $56.01 Million | -- |
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more